Iterum Therapeutics plc (ITRM) P/E Ratio History
Deep ValueTrading at -0.0x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2022–2022
Loading P/E history...
P/E Ratio Analysis
As of June 29, 2026, Iterum Therapeutics plc (ITRM) trades at a price-to-earnings ratio of -0.0x, with a stock price of $0.03 and trailing twelve-month earnings per share of $-0.59.
The current P/E is 100% below its 5-year average of 26.6x. Over the past five years, ITRM's P/E has ranged from a low of 26.6x to a high of 26.6x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.9x, ITRM trades at a 100% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.6x.
Relative to the broader market, ITRM trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ITRM DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ITRM Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ITRM P/E vs Peers
Vaccines and Infectious Disease peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $131M | 15.1Lowest | - | +112%Best | |
| $33B | 24.7 | 0.61Best | +5% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ITRM Historical P/E Data (2022–2022)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2022 Q1 | - | $5.33 | $0.20 | 26.6x | +0% |
Average P/E for displayed period: 26.6x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
4+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ITRM — Frequently Asked Questions
Quick answers to the most common questions about buying ITRM stock.
What is ITRM's P/E ratio?
Iterum Therapeutics plc (ITRM) trailing twelve-month P/E ratio is -0.0x, based on TTM diluted EPS of $-0.59. The 5-year average P/E is 26.6x and the historical range spans 26.6x to 26.6x.
Is ITRM stock overvalued or undervalued?
ITRM current P/E: -0.0x. 5-year average P/E: 26.6x. Percentile: 0th.
Is ITRM stock expensive?
ITRM is fairly valued relative to its own history. The current P/E of -0.0x is near the 5-year average of 26.6x (0th percentile of historical range).
What is ITRM's historical P/E range?
Over the past 5 years, ITRM's P/E ratio has ranged from 26.6x to 26.6x, with a median of 26.6x and an average of 26.6x. The current P/E of -0.0x places the stock at the 0th percentile of this range. Full historical data spans 2022–2022.
How does ITRM's P/E compare to the S&P 500?
ITRM current P/E: -0.0x. S&P 500 median P/E: 25.1x.
How does ITRM's valuation compare to Healthcare peers?
Iterum Therapeutics plc P/E of -0.0x can be benchmarked against Healthcare peers in the comparison table on this page.
What is ITRM's PEG ratio?
ITRM PEG ratio is N/A, based on a P/E of -0.0x and EPS growth of 57.4%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ITRM's earnings yield?
ITRM earnings yield is N/A, the inverse of its -0.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.